US$ 25.52
mounjaro tirzepatide patent expiration us These highlights do not include all the information needed to use safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO® (tirzepatide) Injection, for subcutaneous use Initial U.S. Approval: 2022 Mounjaro (Tirzepatide) Pen | Uses
Description
6 Safety profile GI events (nausea, vomiting, diarrhea) were more common with tirzepatideconsistent with prior incretin trials

Gallbladder problems: Semaglutide may cause gallbladder problems, including gallstones

This innovative medication combines the power of Tirzepatide, a promising new drug for diabetes, with the benefits of compounding pharmacy techniques

Wanneer de behandeling niet passend is of onvoldoende effect zal geven, zijn we daar eerlijk over

To learn more about Lilly Canada, visit Lilly.com/en-CA, or follow us on LinkedIn
.png?v=4d024c233fd53ddcc0af6e3f6f5e3385)